Alterity Therapeutics soared over 36% in premarket trading.Alterity Therapeutics (ASX:ATH) secured a US patent for compounds to treat neurodegenerative diseases, including Parkinson's and Alzheimer's diseases.
The patent covers more than 80 compounds and secures exclusivity for a new class of iron chaperones, which would redistribute excess iron implicated in many neurodegenerative diseases, according to a Thursday news release.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments